Previous 10 | Next 10 |
home / stock / frx:cc / frx:cc news
~ Strong PEDMARK ® Commercial Momentum Building in 2023 with Broad Payor and Medicaid Coverage ~ ~ PEDMARK ® Permanent J-Code Effective April 1, 2023 ~ ~ Recent Positive CHMP Opinion in EU Recommending Approval of PEDMARQSI™ ~ ~ Compa...
RESEARCH TRIANGLE PARK, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2023 financial results before the opening of the U.S. financial...
~ First Therapy Recommended for Approval in the European Union for Reducing the Risk of Cisplatin-induced Hearing Loss (Ototoxicity) in Pediatric Patients with Localized, Non-metastatic Solid Tumors~ ~ Positive CHMP Opinion Based on Clinical Results Demonstrating Prevention of Ototoxici...
~ U.S. Commercial Team in Place with PEDMARK ® Launch Off to Solid Start Following FDA Approval of PEDMARK ® in September 2022 ~ ~ Company Has Approximately $23.8 Million in Cash ~ RESEARCH TRIANGLE PARK, N.C., March 30, 2023 (GLOBE NEWSWIRE) -- Fen...
2023-03-06 12:30:00 ET Most biotech stocks have low visibility with investors because the risks are pretty high. Nonetheless, the TSX has several names worth watching in 2023. Bausch Health ( TSX:BHC ) has appreciated substantially from year-end 2022, and three more could break ...
~ PEDMARK® is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~ ~ Orphan Drug Exclusivity Provides Seven Years of Market Exclusivity for PEDMARK®...
~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-metastatic Solid Tumors ~ ~ The 5-year Survival Rate for Childhood Cancers Due to Major Treatment Advances is Now 85 Per...
~ In September 2022, FDA Approved PEDMARK ® , the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Tumors ~ ~ Initiated U.S. Commercial Launch of PEDMARK ...
~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients ~ ~ Fennec HEARS™ Program Offers Comprehensive Patient Services, Including Access to Care Coordinators, Financial and Prescription Dru...
~ Under the Terms of the Previously Announced Investment Agreement, $5 Million Already Funded Upon Initial Closing, Which Occurred on August 19, 2022, and $20 Million to be Funded Upon FDA Approval of PEDMARK® Which Occurred on September 20, 2022 ~ ~ Fennec Has the Pote...
News, Short Squeeze, Breakout and More Instantly...
Fennec Pharmaceuticals Inc. Company Name:
FRX:CC Stock Symbol:
TSXC Market:
Fennec Pharmaceuticals Inc. Website:
A look at the top 10 most actives in Canada Toronto-Dominion Bank (The) (TD) fell 0.9% to $75.22 on volume of 16,671,142 shares Bank of Nova Scotia (The) (BNS) fell 0.7% to $61.6 on volume of 10,953,303 shares TC Energy Corporation (TRP) fell 1.1% to $51.64 on volume of 10,661,745 shares ...
A look at the top 10 most actives in Canada Fission Uranium Corp. (FCU) rose 5.9% to $1.25 on volume of 21,445,305 shares iShares S&P/TSX 60 Index ETF (XIU) rose 1.4% to $33.6 on volume of 18,474,835 shares TC Energy Corporation (TRP) rose 1.1% to $52.16 on volume of 14,728,718 shares...
RESEARCH TRIANGLE PARK, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that Adrian Haigh has departed from his position as Fennec’s Chief Operating Officer as of June 30, 202...